{"entity":{"id":"paper-grid-regorafenib-gist-lancet-2013","kind":"paper","name":"GRID: regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib","aka":[],"tldr":"Regorafenib delayed progression by almost four months compared with placebo in gastrointestinal stromal tumours resistant to both imatinib and sunitinib, giving patients a third line of targeted therapy.","summary":"Phase 3 placebo-controlled trial of 199 patients with metastatic or unresectable GIST after failure of imatinib and sunitinib randomised 2:1 to regorafenib 160 mg daily (three weeks on, one off) or placebo with crossover at progression.\n\nMedian progression-free survival was 4.8 versus 0.9 months (hazard ratio 0.27) with disease control in 53 versus 9 percent; hypertension, hand-foot skin reaction and diarrhoea were the main toxicities.","asOf":"2026-09-17","links":[{"label":"Lancet 2013","url":"https://doi.org/10.1016/S0140-6736(12)61857-1"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/23177515/"}],"tags":[],"related":[],"cancers":["gist-imatinib-resistant"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib","regorafenib","sunitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["grid"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2013,"doi":"10.1016/S0140-6736(12)61857-1","pmid":"23177515","authors":"Demetri GD, Reichardt P, Kang YK, et al.","paperType":"rct","findings":["Median progression-free survival 4.8 vs 0.9 months; hazard ratio 0.27.","Disease control rate 52.6 percent vs 9.1 percent."],"whatItMeans":"Regorafenib is the standard third-line treatment for GIST after imatinib and sunitinib.","caveats":["No overall survival benefit because of crossover.","Dose reductions needed in most patients."],"changedPractice":true,"participants":199},"route":"/key-papers/paper-grid-regorafenib-gist-lancet-2013/","neighbours":{"cancer":[{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"trial":[{"id":"grid","kind":"trial","name":"GRID","route":"/trials/grid/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}